Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Expedia Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Expedia Group Inc trades at $269.2 (market cap $32.51B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Expedia Group Inc pays a 0.65% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EXPE | |
|---|---|---|
Market Cap | $39.89B | $32.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $301.31 |
52-Week Low | $278.09 | $178.06 |
Enterprise Value | $38.15B | $31.42B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Expedia Group (EXPE) trades at $270.83, up 1.14% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.96 exceeding expectations by 39%. Revenue growth has accelerated from $11.7B in 2022 to $14.7B in 2025, while net income margins improved to 9.81%. Recent developments include the CarTrawler acquisition and AI initiatives, positioning the company for continued travel sector leadership.
Outlook remains positive with analyst consensus target of $285.44 offering 5.4% upside. Key opportunities include travel demand recovery and operational efficiency gains, while risks involve macroeconomic sensitivity and competitive pressures. The stock presents a balanced risk-reward profile with strong institutional support and improving financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
